Home LiteratureArticle Details
PMID: 19348713 Published · ppublish English Journal Article Review

Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.

Current neurology and neuroscience reports ·Vol. 9 ·No. 3 ·2009-05-00 ·Pages 241-6

Clarke JL, Chang S

Abstract

Assessment via MRI is an integral part of the management of primary brain tumors. However, reliance on imaging to determine treatment response is not without its pitfalls. Necrosis is a known late effect of radiation treatment of the brain that can mimic tumor recurrence. It is now appreciated that pseudoprogression, a similar effect, can occur after combined chemoradiotherapy and can occur more quickly and dramatically than after radiation alone. Although several adjunct imaging modalities are under investigation, none is yet widely accepted as being able to distinguish between true progression and pseudoprogression. Conversely, at disease progression, antiangiogenic therapies are frequently used and can have a rapid positive effect on imaging. These changes, increasingly known as "pseudoresponses," can occur immediately after initiating treatment, making accurate assessment of true tumor response difficult. This article reviews the challenges of brain tumor imaging and its use in assessment of treatment response.

MeSH Terms
Antineoplastic Agents/therapeutic use Brain/drug effects,pathology Brain Neoplasms/diagnosis,drug therapy Diagnosis, Differential Diagnostic Imaging/methods Disease Progression Female Humans Image Processing, Computer-Assisted/methods Male
Chemicals
Antineoplastic Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Clarke Jennifer L
Department of Neurological Surgery, Division of Neuro-oncology, University of California-San Francisco, 400 Parnassus Avenue, A-808, Box 0372, San Francisco, CA 94143, USA. [email protected]
Chang Susan
References (27)
27 references, click to expand
  1. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors.
    Magn Reson Imaging. 2001 Jan;19(1):89-101 PMID: 11295350
  2. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    J Clin Oncol. 2007 Oct 20;25(30):4722-9 PMID: 17947719
  3. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
    J Clin Oncol. 2009 Feb 1;27(4):579-84 PMID: 19075262
  4. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
    Cancer. 2008 Jul 15;113(2):405-10 PMID: 18484594
  5. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):997-1003 PMID: 15758010
  6. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    J Nucl Med. 2005 Jun;46(6):945-52 PMID: 15937304
  7. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy.
    AJNR Am J Neuroradiol. 1996 Apr;17(4):737-47 PMID: 8730195
  8. Transient postictal MRI changes in patients with brain tumors may mimic disease progression.
    Surg Neurol. 2007 Mar;67(3):246-50; discussion 250 PMID: 17320628
  9. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
    AJNR Am J Neuroradiol. 2009 Mar;30(3):552-8 PMID: 19056837
  10. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.
    Radiology. 2000 Nov;217(2):377-84 PMID: 11058631
  11. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Neurology. 2008 Mar 4;70(10):779-87 PMID: 18316689
  12. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma.
    Neurology. 2006 Nov 14;67(9):1668-70 PMID: 17101902
  13. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    J Clin Oncol. 2008 May 1;26(13):2192-7 PMID: 18445844
  14. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
    N Engl J Med. 2005 Mar 10;352(10):987-96 PMID: 15758009
  15. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Clin Cancer Res. 2007 Feb 15;13(4):1253-9 PMID: 17317837
  16. Clinical applications of PET in brain tumors.
    J Nucl Med. 2007 Sep;48(9):1468-81 PMID: 17704239
  17. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
    Cancer Cell. 2007 Jan;11(1):83-95 PMID: 17222792
  18. Response criteria for phase II studies of supratentorial malignant glioma.
    J Clin Oncol. 1990 Jul;8(7):1277-80 PMID: 2358840
  19. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
    J Neurooncol. 2007 Mar;82(1):81-3 PMID: 16944309
  20. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?
    AJNR Am J Neuroradiol. 1998 Mar;19(3):407-13 PMID: 9541290
  21. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy.
    J Nucl Med. 2008 May;49(5):694-9 PMID: 18413375
  22. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue.
    AJNR Am J Neuroradiol. 2000 May;21(5):901-9 PMID: 10815666
  23. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET.
    J Neurooncol. 2007 May;82(3):305-11 PMID: 17120157
  24. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.
    AJNR Am J Neuroradiol. 2004 Feb;25(2):201-9 PMID: 14970018
  25. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
    J Clin Oncol. 2008 Oct 1;26(28):4659-65 PMID: 18824712
  26. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.
    AJNR Am J Neuroradiol. 2005 Sep;26(8):1967-72 PMID: 16155144
  27. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
    Neurology. 2006 Apr 25;66(8):1258-60 PMID: 16636248
Article Info
Journal
Current neurology and neuroscience reports
Abbr.
Curr Neurol Neurosci Rep
ISSN
1534-6293
Published
2009-05-00
Pages
241-6
Language
English
Region
United States
NLM ID
100931790
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]